Eiropas Savienība - latviešu - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazona hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. pēc tam, kad sākta terapija ar pioglitazone, pacientiem būtu jāpārskata pēc 3 līdz 6 mēnešiem, lai novērtētu atbilstību ārstēšanas e. samazinājums hba1c). pacientiem, kas nespēj izrādīt pienācīgu atbildi, pioglitazone būtu jāpārtrauc. Ņemot vērā potenciālos riskus, ar ilgstošu terapiju, prescribers jāapstiprina turpmāk kārtējās atsauksmes, ka labā pioglitazone ir saglabāta (skatīt 4. iedaļu.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astrazeneca ab - saksagliptīns - cukura diabēts, 2. tips - cukura diabēts - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

novartis europharm limited - nateglinide - cukura diabēts, 2. tips - cukura diabēts - nateglinīds ir indicēts kombinētai terapijai ar metformīnu 2. tipa diabēta pacientiem, kuri nav pietiekami kontrolēti, neskatoties uz maksimāli panesamo metformīna devu.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi winthrop industrie - insulīna glargine, lixisenatide - cukura diabēts, 2. tips - cukura diabēts - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

novartis europharm ltd. - nateglinide - cukura diabēts, 2. tips - cukura diabēts - nateglinīds ir indicēts kombinētajai terapijai ar metformīnu 2. tipa diabēta pacientiem, kuriem nepietiekami kontrolēta neskatoties uz maksimāli panesamo metformīna devu.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - cukura diabēts, 2. tips - cukura diabēts - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - cukura diabēts - cukura diabēts - Ārstēšana pieaugušajiem ar nepietiekami kontrolēta 2. tipa cukura diabēts, kā palīglīdzekli, lai diētu un vingrošanu:kā monotherapy, ja metformīns tiek uzskatīts par neatbilstošu, jo nepanesība vai kontrindikācijas;papildus citām zālēm, lai ārstētu cukura diabētu. par pētījuma rezultātiem attiecībā uz kombināciju ietekmi uz glycaemic kontroles un sirds un asinsvadu notikumi, un populācijas izpēte, skatīt 4. 4, 4. 5 un 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ammtek - glibenklamīds - cukura diabēts - cukura diabēts - amglidia ir indicēts, lai ārstētu jaundzimušo cukura diabēts, lietot jaundzimušajiem, zīdaiņiem un bērniem. sulphonylureas, piemēram, amglidia ir pierādīts, ka efektīva pacientiem ar mutāciju, kas kodē β-šūnu atp-jutīga kālija kanālu un hromosomu 6q24 saistīti pārejoša jaundzimušo cukura diabēts.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

thompson & capper ltd - tablete